CoChat
Sign Up
Cited by 47Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesBipolar Disorder and Treatment

The DOI matches its Crossref record.

Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study

Rouillon, F., Warner, B., Pezous, N., Bisserbe, J. C.·2000·International Clinical Psychopharmacology
DOI 10.1097/00004850-200015030-00002
Open this paper in CoChat — free account

Abstract

To compare the efficacy and assess the tolerability of milnacipran 50mg p.o. b.i.d. to placebo in the prevention of recurrence in depressed patients who had responded an acute treatment and had remained in remission during a 4-month continuation phase. Remission criteria were: a Hamilton Depression Rating Scale (HDRS) (21-item) < or = 8, improvement or disappearance of the initial symptoms, and an assessment of 'very much improved' or 'much improved' on the Clinical Global Impression (CGI) Subscale: Global Improvement. Recurrence was defined by a major depressive episode according to DSM-III-R criteria and a minimum score of 18 on the HDRS, with the need to treat the recurrence. The primary analysis was the rate of recurrence as a function of time in the intent-to-treat population. Groups were compared using the Cox model. Absolute recurrence rates were 16.3% (17/104) in milnacipran-treated patients and 23.6% (26/110) in placebo-treated patients, with a significant difference in the reduction of recurrence as a function of time (Kaplan Meier Survival Analysis analysis, P < 0.05). There was no difference in tolerability between groups. This study demonstrates that milnacipran is effective with good tolerability in preventing recurrence in major depressive disorder over 1 year in patients with recurrent depression who responded to acute treatment with milnacipran and continued their response for 18 weeks.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004850-200015030-00002

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • One double-blind randomized placebo-controlled trial reported that levomilnacipran outperformed placebo in relapse rate at study-endpoint, while another did not report the statistical result; one trial investigating milnacipran also did not report statistical results.

    “One DBRPCT reported that levomilnacipran outperformed placebo in terms of relapse rate at the study-endpoint [22], while another DBRPCT did not report the statistical result of the outcome [49]; one trial investigating milnacipran also did not report the statistical results [47].”

    From Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis (2023) · cites this paper as [47]

Citations

Cites

Still being checked.

Cited by

Sorted by citations

Related

Metadata

Authors
Rouillon, F., Warner, B., Pezous, N., & Bisserbe, J. C.
Affiliations
Hôpital Albert-Chenevier (FR)
Corresponding author
Rouillon, F.
ORCID
Venue
International Clinical Psychopharmacology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2000-05
Volume
15
Issue
3
Pages
133-140
ISSN
0268-1315 (ISSN-L)
DOI
10.1097/00004850-200015030-00002
OpenAlex
W2023452650
Cited by
47
References
0
Citations by year
2026: 1 · 2025: 2 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 1 · 2016: 1 · 2015: 2 · 2013: 1
FWCI
1.76
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
milnacipran, recurrent depression, depression recurrence prevention, major depressive disorder, continuation phase, remission, antidepressant efficacy, drug tolerability, selective serotonin reuptake inhibitors
MeSH terms
Milnacipran, Adult, Antidepressive Agents, Cyclopropanes, Depressive Disorder, Female, Humans, Male, Middle Aged, Recurrence, Treatment Outcome, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review